Several landmark studies have suggested that when cancer cells are subjected to therapeutic pressure during anti-EGFR therapy, they acquire secondary genetic alterations in a process known as clonal evolution, which may contribute to drug resistance. This evidence concerns the gene EGFR and cancer.